Streetbeat News

Regulatory

STLA

Stellantis NV is recalling nearly 21,000 plug-in hybrid SUVs in the U.S. due to a potential issue with the brake pedal disengaging. The recall affects 2024-2025 Alfa Romeo Tonale and 2024 Dodge Hornet PHEV SUVs. Stellantis will fix the issue at no cost to customers. The company is also recalling other models for different issues.

Portfolio Pulse from Anan Ashraf

October 16, 2024 | 11:47 am

NVCR

NovoCure shares rise following FDA approval of Optune Lua for metastatic non-small cell lung cancer treatment. HC Wainwright & Co. upgrades the stock to Buy and raises the price target from $24 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:39 am

ALZN

Alzamend Neuro announced that the identified dose for their treatment is unlikely to require lithium therapeutic drug monitoring, which could simplify the treatment process and potentially enhance patient compliance.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

NVCR

The FDA has approved NovoCure's Optune Lua, a portable device that uses tumor-treating electric fields, for use with certain inhibitors or docetaxel in treating metastatic non-small cell lung cancer. The approval follows positive results from the Phase 3 LUNAR study, showing significant improvements in overall survival rates. NovoCure's stock (NVCR) rose by 26.20% following the news.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 11:28 am

IVVD

Invivyd is set to present data from its Phase 1 and Phase 3 clinical trials of Pemivibart at IDweek 2024 in Los Angeles. The conference will take place from October 16-19, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:16 am

BLRX

BioLineRx has announced that the United States Patent and Trademark Office (USPTO) has allowed a new composition of matter patent for Motixafortide. This patent strengthens BioLineRx's intellectual property portfolio and could enhance its competitive position in the market.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:07 am

OKYO

OKYO Pharma has commenced patient screening and recruitment for a Phase 2 trial of OK-101 for neuropathic corneal pain. The trial will involve 48 patients and aims to measure pain relief using the Visual Analog Scale.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:05 am

CGEM

Cullinan Therapeutics has received FDA clearance for its investigational new drug application for CLN-978. The company can now proceed with a global Phase 1 trial in the U.S. to assess CLN-978 in patients with moderate to severe systemic lupus erythematosus.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:02 am

ACET

Adicet Bio's stock is rising following the FDA's clearance of an IND amendment to study ADI-001 for idiopathic inflammatory myopathy and stiff person syndrome.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:02 am

ACET

Adicet Bio has received FDA clearance for an IND amendment to evaluate ADI-001 in treating idiopathic inflammatory myopathy and stiff person syndrome. This development could potentially expand the therapeutic applications of ADI-001.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:01 am